Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
November 29 2022 - 8:30AM
Business Wire
- Presenting data evaluating LP352 engagement of central 5-HT2C
receptors via effects on prolactin, and assessing binding activity
and functional agonism of LP352 at the 5-HT2 receptors
- Hosting scientific exhibit highlighting the ongoing Phase 1b/2a
PACIFIC Study, and LP352, a novel, highly selective 5-HT2C
superagonist in development for rare seizure disorders
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will present data for LP352, a novel, highly selective
investigational treatment in development for seizures associated
with a range of developmental and epileptic encephalopathies
(DEEs), in two poster sessions at the 2022 AES Annual Meeting.
Longboard will also host a scientific exhibit with members of its
leadership team to highlight details of the ongoing PACIFIC study,
and to discuss LP352 as a potential best-in-class therapy for
people living with rare seizure disorders.
“We are committed to improving the lives of people living with
rare epilepsies, and are pleased to have a meaningful presence at
AES this year. We look forward to presenting data highlighting the
intrinsic characteristics of LP352, as well as hosting discussions
around our ongoing PACIFIC study and future development plans. We
believe that LP352 has the promise to be a best-in-class therapy
for a broad range of DEEs, and make a difference in these
devastating conditions,” stated Dr. Randall Kaye, Longboard’s Chief
Medical Officer.
Presentation & Event Details: Title:
Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess
Engagement of Central 5-HT2C Receptors by LP352, a Potent and
Selective 5-HT2C Agonist Poster number: 1.290
Date/Time: December 3, 2022, from 12:00-2:00pm ET
Title: Searching for Safer and More Effective Medications
in the Management of Seizure Disorders: A 5-HT2C Superagonist
Poster number: 2.260 Date/Time: December 4, 2022,
from 12:00-2:00pm ET
Longboard Scientific Exhibit: A Novel 5-HT2C Superagonist
for Treatment of Rare Seizure Disorders: LP352 and the PACIFIC
Study Date/Time: December 5, 2022, from 2:00-5:00pm ET
Location: Room 207 A&B, Music City Center, Nashville,
TN
About Longboard Pharmaceuticals Longboard
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on developing novel, transformative medicines for
neurological diseases. Longboard is working to advance a portfolio
of centrally acting product candidates designed to be highly
selective for specific G protein-coupled receptors (GPCRs).
Longboard’s small molecule product candidates are based on more
than 20 years of GPCR research. Longboard is evaluating LP352, an
oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor
superagonist, with negligible observed impact on 5-HT2B and 5-HT2A
receptor subtypes, in development for the potential treatment of
seizures associated with a broad range of developmental and
epileptic encephalopathies (DEEs). LP352 is currently being
evaluated in a Phase 1b/2a clinical trial, the PACIFIC Study, for
the potential treatment of seizures associated with DEEs. Longboard
is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system diseases and disorders.
Forward-Looking Statements Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about LP352’s potential to be a best-in-class therapy,
Longboard’s participation in the upcoming 2022 AES annual meeting,
Longboard’s clinical and preclinical programs, its ability to
develop and deliver therapies, and its focus. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements are disclosed in Longboard’s
filings with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221129005353/en/
Corporate Contact: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024